The Center has consolidated research administration into one unit, to align more appropriately with the reorganized CCSG Program structure. It provides centralized corporate sen/ices, maintains single Center wide operating committees, and has centrally managed research facilities/services to promote efficiency and effectiveness. The research administrative team at Fox Chase Cancer Center (FCCC) primarily consists of the Vice President for Research Administration, an Assistant Vice President and a Shared Facility Administrator. These individuals are experienced in all aspects of research administration and participate in national research administrative groups, such as the Alliance of Dedicated Cancer Centers, the National Council of University Administrators and the Cancer Centers Administrators Forum. In addition to the time spent in research administration, the three key individuals have various Center-wide administrative responsibilities. Collectively, these three individuals provide the administrative support to all Cancer Center Programs and centralized scientific shared Facilities. They work closely with the Center President and Senior Vice Presidents on important Center initiatives (see Senior Leadership Description section) and they serve as administrative representatives on Center-wide committees. Each is supported by a staff that works in tandem to provide budgetary, grants management, space planning, and post-award support to investigators. A single administrator has responsibility for managing the CCSG. This individual oversees all financial transactions of CCSG Facilities, coordinates the annual progress report, manages the CCSG budget and assures compliance with CCSG regulations. Certain research grant functions have been centralized to achieve efficiency and effectiveness for all Center investigators. These centralized departments routinely interact with Research Administration. The centralized management provides for checks and balances in meeting NIH and other agency grant regulations. All pre-award activities (grant budgets, compliance with funding agency regulations and completion of most administrative application documents) are coordinated through our Office of Sponsored Research. All post-award activities (monitoring effort reports, reviewing grant charges, overseeing subcontracting activities, and filing final financial reports) are coordinated through our Grants Management Department. Policies are in place to allocate and manage institutional funds that support research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-49
Application #
8379798
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
49
Fiscal Year
2012
Total Cost
$143,447
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Boland, Patrick M; Meyer, Joshua E; Berger, Adam C et al. (2016) Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol :
Heckman, Carolyn J; Handorf, Elizabeth A; Darlow, Susan D et al. (2016) An Online Skin Cancer Risk-Reduction Intervention for Young Adults: Mechanisms of Effects. Health Psychol :
Meropol, Neal J; Wong, Yu-Ning; Albrecht, Terrance et al. (2016) Randomized Trial of a Web-Based Intervention to Address Barriers to Clinical Trials. J Clin Oncol 34:469-78
Hayakawa, K; Formica, A M; Colombo, M J et al. (2016) Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells. Leukemia 30:1510-9
Tan, Yinfei; Xin, Xiaoban; Coffey, Francis J et al. (2016) Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. J Cell Physiol 231:1142-50
Duong-Ly, Krisna C; Devarajan, Karthik; Liang, Shuguang et al. (2016) Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases. Cell Rep 14:772-81
Meeker, Caitlin R; Geynisman, Daniel M; Egleston, Brian L et al. (2016) Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. J Oncol Pract 12:e755-64
Geynisman, Daniel M; Handorf, Elizabeth; Wong, Yu-Ning et al. (2016) Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer Med 5:192-9
Kurimchak, Alison M; Shelton, Claude; Duncan, Kelly E et al. (2016) Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. Cell Rep 16:1273-86
Borczuk, Alain C; Pei, Jianming; Taub, Robert N et al. (2016) Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biol Ther 17:328-35

Showing the most recent 10 out of 884 publications